Ocular antisense oligonucleotide delivery by cationic nanoemulsion for improved treatment of ocular neovascularization: An in-vivo study in rats and mice

Journal of Controlled Release

Volumn 160, Issue 2, 2012, Pages 225-231

  Hagigit, Tal ^a   Abdulrazik, Muhammad ^a   Valamanesh, Faty ^b   Behar Cohen, Francine ^b,c,d   Benita, Simon ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b CENTRE DE RECHERCHE DES CORDELIERS   (France)

^c HÔTEL DIEU   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Age related Macular Degeneration (AMD); Antisense oligonucleotides; Cationic; DOTAP; Nanoemulsion; VEGF

Indexed keywords

AGE-RELATED MACULAR DEGENERATION; ANTISENSE OLIGONUCLEOTIDES; CATIONIC; DOTAP; NANOEMULSION; VEGF;

OPHTHALMOLOGY;

RATS;

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; ANTISENSE OLIGONUCLEOTIDE; BEVACIZUMAB; ODN 17; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTISENSE THERAPY; ARTICLE; CONTROLLED STUDY; CORNEA NEOVASCULARIZATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; IN VIVO STUDY; MALE; MOUSE; NANOEMULSION; NONHUMAN; PRIORITY JOURNAL; RAT; RETINA NEOVASCULARIZATION; RETROLENTAL FIBROPLASIA;

ANGIOGENESIS INHIBITORS; ANIMALS; CATIONS; CORNEAL NEOVASCULARIZATION; DISEASE MODELS, ANIMAL; DRUG CARRIERS; EMULSIONS; FATTY ACIDS, MONOUNSATURATED; HUMANS; INFANT, NEWBORN; MALE; MICE; MICE, INBRED C57BL; NANOSTRUCTURES; OLIGONUCLEOTIDES, ANTISENSE; QUATERNARY AMMONIUM COMPOUNDS; RATS; RATS, SPRAGUE-DAWLEY; RETINOPATHY OF PREMATURITY; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; VITREOUS BODY;

EID: 84861657127     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2011.11.022     Document Type: Article

References (29)

1. A. Tezel, S. Dokka, S. Kelly, G.E. Hardee, and S. Mitragotri Topical delivery of anti-sense oligonucleotides using low-frequency sonophoresis Pharm. Res. 21 2004 2219 2225
2. X. Zhao, F. Pan, C.M. Holt, A.L. Lewis, and J.R. Lu Controlled delivery of antisense oligonucleotides: a brief review of current strategies Expert Opin. Drug Deliv. 7 2009 673 686
3. 14C-labled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats J. Pharmacol. Exp. Ther. 267 1993 1181 1190
4. S. Agrawal, J. Temsamani, and J.Y. Tang Pharmacokinetics, biodistribution and stability of oligonucleotide phosphorothioates in mice Proc. Natl. Acad. Sci. U. S. A. 88 1991 7595 7599
5. 3H-labeled oligonucleotides. I. Comparison of a phosphodiester and a phosphorothioated Mol. Pharmacol. 45 1994 932 943
6. P.S. Eder, R.J. DeVine, J.M. Dagle, and J.A. Walder Substrate specificity and kinetics of degradation of antisense oligonucleotides by a 3′ exonuclease in plasma Antisense Res. Dev. 1 1991 141 151
7. A. Chiang, and C.D. Regillo Preferred therapies for neovascular age-related macular degeneration Curr. Opin. Ophthalmol. 3 2011 199 204
8. M.A. Zarbin Rosenfeld PJ Pathway-based therapies for age-related macular degeneration: an integrated survey of emerging treatment alternatives. Retina 9 2010 1350 1367
9. J.P. Hubschman, S. Reddy, and S.D. Schwartz Age-related macular degeneration: current treatments Clin. Ophthalmol. 3 2009 155 166
10. H. Teixeira, C. Dubernet, F. Puisieux, S. Benita, and P. Couvreur Submicron cationic emulsions as a new delivery system for oligonucleotides Pharm. Res. 16 1999 30 36
11. C. Andrieu-Soler, R.A. Bejjani, T. de Bizemont, N. Normand, D. BenEzra, and F. Behar-Cohen Ocular gene therapy: a review of nonviral strategies Mol. Vis. 12 2006 1334 1347
12. H. Teixeira, C. Dubernet, V. Rosilio, A. Laigle, R.R. Deverre, D. Scherman, S. Benita, and P. Couvreur Factors influencing the oligonucleotides release from O/W submicron cationic emulsions J. Control. Release 70 2001 243 255
13. T. Hagigit, T. Nassar, F. Behar-Cohen, G. Lambert, and S. Benita The influence of cationic lipid type on in-vitro release kinetic profiles of antisense oligonucleotide from cationic nanoemulsions Eur. J. Pharm. Biopharm. 70 2008 248 259
14. T. Hagigit, M. Abdulrazik, F. Orucov, F. Valamanesh, M. Hagedorn, G. Lambert, F. Behar-Cohen, and S. Benita Topical and intravitreous administration of cationic nanoemulsions to deliver antisense oligonucleotides directed towards VEGF KDR receptors to the eye J. Control. Release 145 2010 297 305
15. S. Tamilvanan, and S. Benita The potential of lipid emulsion for ocular delivery of lipophilic drugs Eur. J. Pharm. Biopharm. 58 2004 357 368
16. J.M. Mahoney, and L.D. Waterbury Drug effects on the neovascularization response to silver nitrate cauterization of the rat cornea Curr. Eye Res. 4 1985 531 535
17. G.A. Peyman, M. Kivilcim, A.M. Morales, J.T. Dellacroce, and M.D. Conway Inhibition of corneal angiogenesis by ascorbic acid in the rat model Graefes Arch. Clin. Exp. Ophthalmol. 245 2007 461 467
18. L.E. Smith, E. Wesolowski, A. McLellan, S.K. Kostyk, R. D'Amato, R. Sullivan, and P.A. D'Amore Oxygen-induced retinopathy in the mouse Investig. Ophthalmol. Vis. Sci. 35 1994 101 111
19. H.E. Grossniklaus, S.J. Kang, and L. Berglin Animal models of choroidal and retinal neovascularization Prog. Retin. Eye Res. 29 2010 500 519
20. L. Rabinovich-Guilatt, P. Couvreur, G. Lambert, D. Goldstein, S. Benita, and C. Dubernet Extensive surface studies help to analyse zeta potential data: the case of cationic emulsions Chem. Phys. Lipids 131 2004 1 13
21. R.P. Manzano, G.A. Peyman, P. Khan, P.E. Carvounis, M. Kivilcim, M. Ren, J.C. Lake, and P. Chévez-Barrios Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin) Br. J. Ophthalmol. 91 2007 804 807
22. S.H. Klang, C.S. Siganos, S. Benita, and J. Frucht-Pery Evaluation of a positively charged submicron emulsion of piroxicam on the rabbit corneum healing process following alkali burn J. Control. Release 57 1999 19 27
23. S.H. Klang, M. Abdulrazik, and S. Benita Influence of emulsion droplet surface charge on indomethacin ocular tissue distribution Pharm. Dev. Technol. 5 2000 521 532
24. S. Tamilvanan, K. Khoury, D. Gilhar, and S. Benita Ocular delivery of cyclosporin A I. Design and characterization of cyclosporin A-loaded positively-charged submicron emulsion S.T.P. Pharma Sci. 11 2001 315 320
25. M. Abdulrazik, S. Tamilvanan, K. Khoury, and S. Benita Ocular delivery of cyclosporin A II. Effect of submicron emulsion's surface charge on ocular distribution of topical cyclopsorin A S.T.P. Pharma Sci. 11 2001 321 326
26. O. Harush-Frenkel, Y. Altschuler, and S. Benita Nanoparticle-cell interactions: drug delivery implication Crit. Rev. Ther. Drug Carrier Syst. 25 2008 485 544
27. Y. Gong, and D.R. Koh Neutrophils promote inflammatory angiogenesis via release of preformed VEGF in an in vivo corneal model Cell Tissue Res. 339 2010 437 448
28. J.Y. Oh, M.K. Kim, M.S. Shin, H.J. Lee, J.H. Lee, and W.R. Wee The anti-inflammatory effect of subconjunctival bevacizumab on chemically burned rat corneas Curr. Eye Res. 34 2009 85 91
29. S.A. Vinores, C.C. Chan, M.A. Vinores, D.M. Matteson, Y.S. Chen, D.A. Klein, A. Shi, H. Ozaki, and P.A. Campochiaro Increased vascular endothelial growth factor (VEGF) and transforming growth factor beta (TGFbeta) in experimental autoimmune uveoretinitis: upregulation of VEGF without neovascularization J. Neuroimmunol. 89 1998 43 50